Actions of tacrine and galanthamine on histamine-N-methyltransferase

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 27, Issue 3, 2005, Pages 161-165

  Taraschenko, O D ^a   Barnes, W G ^a   Herrick Davis, K ^a   Yokoyama, Y ^a   Boyd, D L ^a   Hough, Lindsay B ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Alzheimer's disease; Galanthamine; Histamine N methyltransferase; Tacrine

Indexed keywords

GALANTAMINE; HISTAMINE; HISTAMINE METHYLTRANSFERASE; HISTAMINE RECEPTOR; TACRINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN; COGNITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; HISTAMINE METABOLISM; HUMAN; HUMAN TISSUE; IC 50; KIDNEY CELL; MALE; NONHUMAN; RAT;

ANIMALS; BRAIN; CLONING, MOLECULAR; DNA, COMPLEMENTARY; ENZYME INHIBITORS; GALANTAMINE; HISTAMINE N-METHYLTRANSFERASE; HUMANS; KIDNEY; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TACRINE;

EID: 17644418402     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2005.27.3.890872     Document Type: Article

References (38)

1. Hough, L.B. Histamine. In: Basic Neurochemistry. Siegel, G.J., Agranoff, B.W., Albers, R.W., Fisher, S.K., Uhler, M.D. (Eds.). Lippincott-Raven: Philadelphia 1999, 293-313.
2. Schwartz, J.C., Arrang, J.M., Garbarg, M., Pollard, H., Ruat, M. Histaminergic transmission in the mammalian brain. Physiol Rev 1991, 71: 1-51.
3. Verburg, K.M., Henry, D.P. Histamine N-methyltransferase. In: Neuromethods: Neurotransmitter Enzymes. Boulton, A.A., Baker, G.B., Yu, P.H., Clifton, N.J. (Eds.). Humana Press 1986, 147-204.
4. Horton, J.R., Sawada, K., Nishibori, M., Zhang, X., Cheng, X. Two polymorphic forms of human histamine methyltransferase: Structural, thermal, and kinetic comparisons. Structure (Camb.) 2001, 9: 837-49.
5. Nishibori, M., Tahara, A., Sawada, K., Sakiyama, J., Nakaya, N., Saeki, K. Neuronal and vascular localization of histamine N-methyltransferase in the bovine central nervous system. Eur J Neurosci 2000, 12: 415-24.
6. Barnes, W.G., Hough, L.B. Membrane-boundhistamine-N-methyltransferase in mouse brain: Possible role in the synoptic inactivation of neuronal histamine. J Neurochem 2002, 82: 1262-71.
7. Panula, P., Rinne, J., Kuokkanen, K. et al. Neuronal histamine deficit in Alzheimer's disease. Neuroscience 1998, 82: 993-97.
8. Higuchi, M., Yanai, K., Okamura, N. et al. Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 2000, 99: 721-29.
9. Morris, J.C. Clinical presentation and course of Alzheimer's disease. In: Alzheimer's Disease. Terry, R.D., Katzman, R., Bick, K.L., Sisodia, S.S. (Eds.). Lippincott Williams & Wilkins: Philadelphia 1999, 11-25.
10. Bartus, R.T., Dean, R.L., III, Beer, B., Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217: 408-14.
11. Tariot, P.N. Maintaining cognitive function in Alzheimer disease: How effective are current treatments? Alzheimer Dis Assoc Disord 2001, 15: 526-533.
12. Camps, P., Cusack, B., Mallender, W.D. et al. Huprine X is a novel high-affinity inhibitor of acetylcholineslerase that is of interest for treatment of Alzheimer's disease. Mol Pharmacol 2000, 57: 409-17.
13. Cumming, P., Reiner, P.B., Vincent, S.R. Inhibition of rat brain histamine-N-methyltransferase by 9-amino-1,2,3,4-tetrahydroacridine (THA). Biochem Pharmacol 1990, 40: 1345-50.
14. Nishibori, M., Oishi, R., Itoh, Y., Saeki, K. 9-Amino-1,2,3,4- tetrahydroacridine is a potent inhibitor of histamine N-methyltransferase. Jpn J Pharmacol 1991, 55: 539-46.
15. Coyle, J., Kershaw, P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease. Biol Psychiatry 2001, 49: 289-99.
16. Woodruff-Pak, D.S., Vogel, R.W., III, Wenk, G.L. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A 2001, 98: 2089-209.
17. Bowsher, R.R., Verburg, K.M., Henry, D.P. Rat histamine N-methyltransferase. Quantification, tissue distribution, purification, and immunologic properties. J Biol Chem 1983, 258: 12215-2220.
18. Aksoy, S., Raftogianis, R., Weinshilboum, R. Human histamine N-methyltransferase gene: Structural characterization and chromosomal location. Biochem Biophys Res Commun 1996, 219: 548-54.
19. Preuss, C.V., Wood, T.C., Szumlanski, C.L. et al. Human histamine N-methyltransferase pharmacogenetics: Common genetic polymorphisms that alter activity. Mol Pharmacol 1998, 53: 708-17.
20. Verburg, K.M., Bowsher, R.R., Henry, D.P. A new radioenzymatic assay for histamine using purified histamine N-methyltransferase. Life Sci 1983, 32: 2855-67.
21. Geula, C., Mesulam, M. Cholinergic systems in Alzheimer's disease. In: Alzheimers Disease. Terry, R.D., Katzman, R., Bick, K.L., Sisodia, S.S. (Eds.). Lippincott Williams & Wilkins: Philadelphia 1999, 11-25.
22. Pollard, H., Moreau, J., Arrang, J.M., Schwartz, J.C. A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 1993, 52: 169-89.
23. Miyazaki, S., Imaizumi, M., Onodera, K. Effects of thioperamide on the cholinergic system and the step-through passive avoidance test in mice. Methods Find Exp Clin Pharmacol 1995, 17: 653-58.
24. Miyazaki, S., Onodera, K., Imaizumi, M., Timmerman, H. Effects of clobenpropit (VUF-9153), a histamine H3-receptor antagonist, on learning and memory, and on cholinergic and monoaminergic systems in mice. Life Sci 1997, 61: 355-61.
25. Toyota, H., Dugovic, C., Koehl, M. et al. Behavioral characterization of mice lacking histamine H(3) receptors. Mol Pharmacol 2002, 62: 389-97.
26. 3 receptor activation in rats. Br J Pharmacol 1996, 119: 1656-64.
27. Leurs, R., Blandina, P., Tedford, C., Timmerman, H. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci 1998, 19: 177-83.
28. Passani, M.B., Bacciottini, L., Mannaioni, P.F., Blandina, P. Central histaminergic system and cognition. Neurosci Biobehav Rev 2000, 24: 107-13.
29. Morisset, S., Traiffort, E., Schwartz, J.C. inhibition of histamine versus acetylcholine metabolism as a mechanism of tacrine activity. Eur J Pharmacol 1996, 315: R1-R2.
30. Nielsen, J.A., Mena, E.E., Williams, I.H., Nocerini, M.R., Liston, D. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol 1989, 173: 53-64.
31. Grothe, D.R., Piscitelli, S.C., Dukoff, R., Fullerton, T., Sunderland, T., Molchan, S.E. Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer's disease. J Clin Psychopharmacol 1998, 18: 78-81.
32. Johansson, M., Hellstrom-Lindahl, E., Nordberg, A. Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer's patients. Dementia 1996, 7(2): 111-17.
33. Harle, D.O., Baldo, B.A. Structural features of potent inhibitors of rat kidney histamine N-methyltransferase. Biochem Pharmacol 1988, 37: 385-8.
34. Grassmann, S., Apelt, J., Sippl, W. et al. Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH(3) receptor affinities. Bioorg Med Chem 2003, 11: 2163-74.
35. Robert, P. Understanding and managing behavioral symptoms in Alzheimer's disease and related dementias: Focus on rivastigmine. Curr Med Res Opin 2002, 18: 156-71.
36. Malaguarnera, M., Pistone, G., Vinci, M., Motta, M., di Fazio, I., Rampello, L. Tacrine treatment of Alzheimer's disease: Many expectations, fewer certainties. Neuropsychobiology 1998, 38: 226-31.
37. Samuels, S.C., Davis, K.L. A risk-benefit assessment oftacrine in the treatment of Alzheimer's disease. Drug Saf 1997, 16: 66-77.
38. Orgogozo, J.M., Small, G.W., Hammond, G., Van Baelen, B., Schwalen, S. Effects of galanthamine in patients with mild Alzheimer's disease. Curr Med Res Opin 2004, 20: 1815-20.